###begin article-title 0
Complex genetic predisposition in adult and juvenile rheumatoid arthritis
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
Rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA) are complex multifactorial diseases caused by environmental influences and an unknown number of predisposing genes. The present study was undertaken in order to investigate association of polymorphisms in candidate genes with RA and JRA in German subjects.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 105 113 105 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFa</italic>
###xml 121 133 121 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA -238a/g</italic>
###xml 135 147 135 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA -308a/g</italic>
###xml 149 161 149 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA -857c/t</italic>
###xml 163 176 163 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR1 -609g/t</italic>
###xml 178 188 178 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR1 P12P</italic>
###xml 190 204 190 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR2 del 15bp</italic>
###xml 206 218 206 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL -332a/g</italic>
###xml 220 232 220 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL -132t/a</italic>
###xml 234 244 234 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL C224R</italic>
###xml 246 259 246 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 -318c/t</italic>
###xml 261 271 261 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 T17A</italic>
###xml 273 283 273 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC P57P</italic>
###xml 285 296 285 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF -173g/c</italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNG </italic>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 689 697 <span type="species:ncbi:9606">patients</span>
Up to 200 unrelated German RA and JRA patients each and 300-400 healthy controls have been genotyped for HLA-DRB1, TNFa, TNFA -238a/g, TNFA -308a/g, TNFA -857c/t, TNFR1 -609g/t, TNFR1 P12P, TNFR2 del 15bp, IKBL -332a/g, IKBL -132t/a, IKBL C224R, CTLA4 -318c/t, CTLA4 T17A, PTPRC P57P, MIF -173g/c, the MIF and IFNG microsatellites as well as for D17S795, D17S807, D17S1821 by polyacrylamide gel electrophoresis, single-strand conformation polymorphism analysis, restriction fragment length polymorphism analysis or allele specific hybridization. None of the investigated genetic markers is associated with both, RA and JRA, but there are some statistically significant differences between patients and controls that have to be discussed sensibly.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
The difficulty in investigating the genetics of complex disorders like RA and JRA may arise from genetic heterogeneity in the clinically defined disease cohorts (and generally limited power of such studies). In addition, several to many genes appear to be involved in the genetic predisposition, each of which exerting only small effects. The number of investigated patients has to be increased to establish the possibility of subdivison of the patients according their clinical symptoms, severity of disease, HLA status and other genetic characteristics.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 619 620 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 686 695 686 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 704 705 704 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 712 720 712 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 773 774 773 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 963 964 963 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 40 42 <span type="species:ncbi:9606">RA</span>
###xml 250 252 <span type="species:ncbi:9606">RA</span>
###xml 352 354 <span type="species:ncbi:9606">RA</span>
###xml 644 646 <span type="species:ncbi:9606">RA</span>
Rheumatoid arthritis in adult patients (RA) is probably not a single pathogenetic entity leading to a chronic autoimmune disease resulting in the destruction of joints. The subforms cannot yet be distinguished clinically. The worldwide prevalence of RA is about 1% and the precise etiology is still unknown [1]. Multifactorial origins are supposed for RA meaning that environmental factors as well as the contributions of several to many genes appear to play a role in the development of the disease. The genetic component is emphasized by a 3-4 fold higher concordance rate in monozygotic compared to dizygotic twins [2]. The manifestation of RA is known to be associated with certain HLA-DRB1 alleles [3]. The DRB1*04 association has been confirmed for many populations [1]. The associated alleles encode five amino acids at positions 70-74 of the HLA-DRB1 chain. This so-called shared epitope (SE) comprises of the amino acid sequences QKRAA, QRRAA and RRRAA [4]. The functional basis of the SE association has still to be clarified.
###end p 8
###begin p 9
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 638 639 638 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 745 746 745 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 749 761 749 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*01 </italic>
###xml 765 769 765 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*04 </italic>
###xml 871 883 871 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 977 978 977 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 981 989 981 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*01 </italic>
###xml 1100 1101 1100 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1150 1158 1150 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*08 </italic>
###xml 1162 1166 1162 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*11 </italic>
###xml 1167 1169 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 967 975 <span type="species:ncbi:9606">children</span>
###xml 1048 1056 <span type="species:ncbi:9606">patients</span>
Juvenile rheumatoid arthritis (JRA) designates a group of diseases that have in common chronic idiopathic inflammation of one or more joints. According to the clinical spectrum JRA can be divided into at least three subtypes including pauciarticular, polyarticular and systemic onset with extraarticular manifestations as vasculitis, scleritis etc. [5]. The pauciarticular type is characterized by the involvement of one to four joints (monoarticular, oligoarticular), the polyarticular type involves five or more joints. The presence of autoantibodies and T cell clonality primarily seen in the joints points to autoimmune pathogenesis [6]. The prevalence of JRA varies worldwide among different ethnic and geographically distinct populations [7]. HLA-DRB1*01 and *04 alleles have been repeatedly reported to increase the risk for polyarticular JRA in many populations. HLA-DRB1*04 is highly associated with IgM rheumatoid factor-positive polyarticular JRA in older children [8]. DRB1*01 is associated with pauciarticular disease onset in younger patients, changing to a polyarticular course later [9]. Further associated HLA associated alleles are DRB1*08 and *11 [10].
###end p 9
###begin p 10
###xml 521 527 521 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA) </italic>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 871 876 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 926 932 926 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR1 </italic>
###xml 936 942 936 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR2 </italic>
###xml 1028 1034 1028 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL) </italic>
###xml 1139 1141 1139 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 21 23 <span type="species:ncbi:9606">RA</span>
###xml 345 347 <span type="species:ncbi:9606">RA</span>
###xml 703 705 <span type="species:ncbi:9606">RA</span>
###xml 706 714 <span type="species:ncbi:9606">patients</span>
###xml 1131 1133 <span type="species:ncbi:9606">RA</span>
Since both diseases, RA and JRA, share an autoimmune background as well as other pathogenetic features, the same candidate genes can be considered primarily. These susceptibility genes include an immense number of genes encoding cytokines, their receptors and other immunorelevant genes playing possibly significant roles in the pathogenesis of RA and JRA. A most enigmatic chromosomal region for susceptibility to autoimmune disorders is the HLA region on 6p21. This region harbors also the tumor necrosis factor alpha (TNFA) locus, for which several associations with autoimmune diseases have been described [11,12]. In addition, the presence of increased levels of TNF in serum and synovial fluid of RA patients promoting tissue damage and joint destruction necessitate that this genomic region is investigated. Therefore, several polymorphisms in the promotor of the TNFA gene on 6p21 as well as in the TNF receptor genes TNFR1 and TNFR2 were included. The inhibitor of kappa light chain gene enhancer in B cells-like gene (IKBL) is also located in the HLA region and therefore can be considered as a potent candidate gene for RA/JRA [13].
###end p 10
###begin p 11
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 369 375 369 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 203 205 <span type="species:ncbi:9606">RA</span>
Cytotoxic T lymphocyte-associated protein 4 (CTLA4) is expressed on activated T cells and thus it is critically involved in the immune response [14,15]. Previous studies on multifactorial disorders like RA, insulin-dependent diabetes mellitus, multiple sclerosis (MS) and some other autoimmune diseases investigated in different populations suggested associations with CTLA4 polymorphisms [16-21].
###end p 11
###begin p 12
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
Protein-tyrosine phosphatase receptor-type C (PTPRC, also known as CD45) is expressed on leukocytes and hematopoietic progenitors [22]. This receptor is involved in T and B cell activation and in signal transduction by regulating protein-tyrosine kinases. The protein is found in multiple isoforms, depending on alternative splicing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC) (CD45RO, exon 4-6 spliced out).
###end p 12
###begin p 13
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 130 136 <span type="species:ncbi:9606">humans</span>
###xml 185 187 <span type="species:ncbi:9606">RA</span>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
Expression of macrophage migration inhibitory factor (MIF) correlates well with delayed hypersensitivity and cellular immunity in humans. MIF activity can be detected in the synovia of RA patients. The suggested role for MIF includes mediator function in regulating macrophage action in host defense [23,24].
###end p 13
###begin p 14
###xml 145 147 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 177 182 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNG </italic>
###xml 205 207 201 203 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 234 236 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 318 326 310 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 448 450 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 550 552 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 553 555 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 487 489 <span type="species:ncbi:9606">RA</span>
Interferon gamma (IFNgamma) is produced by T lymphocytes in response to antigens to which they are sensitized. It displays antiviral activities [25]. In the first intron of the IFNG gene a polymorphic (CA)n microsatellite is located [26]. Microsatellite allele 02 is associated with high levels of IFNgamma production in vitro, which may be due to its association with a linked SNP within a putative NFkappaB (nuclear factor kappa B) binding site [27]. Susceptibility to and severity of RA are associated to different alleles of this microsatellite [28-31].
###end p 14
###begin p 15
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL</italic>
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC</italic>
###xml 20 24 20 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNG </italic>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 91 93 <span type="species:ncbi:9606">RA</span>
###xml 414 420 <span type="species:ncbi:9606">humans</span>
###xml 483 488 <span type="species:ncbi:9606">human</span>
###xml 580 582 <span type="species:ncbi:9606">RA</span>
###xml 645 648 <span type="species:ncbi:10116">rat</span>
###xml 659 661 <span type="species:ncbi:9606">RA</span>
IKBL, CTLA4, PTPRC, MIF and IFNG only are selected examples for potent candidate genes for RA association. They all are involved in immunological processes and are different parts of signalling cascades. Another approach to elucidate the genetic background of complex diseases is to draw parallels from animal models providing important information concerning which candidate genes or regions should be studied in humans. This strategy was successful in the investigation of several human autoimmune diseases like MS or type 1 insulin dependent diabetes mellitus [32,33]. A novel RA susceptibility locus on 17q22 homologous to one linked to two rat models of RA was found by linkage and association mapping [34].
###end p 15
###begin p 16
###xml 65 67 <span type="species:ncbi:9606">RA</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 328 330 <span type="species:ncbi:9606">RA</span>
To reveal genetic predisposition factors of the complex diseases RA and JRA, in this study many polymorphisms in candidate genes have been genotyped in cohorts of about 200 patients. Since many of the already reported associations have not been replicated in all independent data sets, we compared the allele frequencies in our RA and JRA cohorts with those of controls in order to contribute to define general associations.
###end p 16
###begin title 17
Results
###end title 17
###begin p 18
###xml 19 28 19 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 55 56 55 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 180 188 180 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 232 234 232 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 282 288 282 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1* </italic>
###xml 296 299 296 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">08 </italic>
###xml 303 306 303 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">11 </italic>
###xml 95 97 <span type="species:ncbi:9606">RA</span>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 200 202 <span type="species:ncbi:9606">RA</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
The results of the HLA-DRB1 typing are shown in figure 1. The DNA of 367 healthy controls, 190 RA patients and 130 JRA patients has been analysed. The described association of the DRB1*04 allele with RA is confirmed in our cohort (pc < 0.001) [35]. In the group of JRA patients the DRB1* alleles 08 and 11 are highly represented, but the differences are not statistically significant.
###end p 18
###begin p 19
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 86 88 <span type="species:ncbi:9606">RA</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 134 137 <span type="species:ncbi:9606">JRA</span>
HLA-DRB1 allele frequencies in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheumatoid arthritis patients (JRA).
###end p 19
###begin p 20
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 136 138 136 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 169 171 169 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 116 119 <span type="species:ncbi:9606">JRA</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Figure 2 shows the distribution of alleles of the TNFa microsatellite. Allele 06 is overrepresented in the group of JRA patients (17.1% vs. 11.0% in the control group, pc < 0.02).
###end p 20
###begin p 21
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFa </italic>
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 104 106 <span type="species:ncbi:9606">RA</span>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 152 155 <span type="species:ncbi:9606">JRA</span>
Allele frequencies of the TNFa microsatellite in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheumatoid arthritis patients (JRA).
###end p 21
###begin p 22
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 167 173 163 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR1 </italic>
###xml 177 182 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR2</italic>
###xml 221 226 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 278 283 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 362 363 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">2</xref>
###xml 588 594 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR1 </italic>
###xml 732 733 728 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">2</xref>
###xml 800 806 796 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR2 </italic>
###xml 1122 1123 1118 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">2</xref>
###xml 1132 1133 1128 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1143 1148 1139 1144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 1305 1306 1301 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">2</xref>
###xml 432 440 <span type="species:ncbi:9606">patients</span>
###xml 715 717 <span type="species:ncbi:9606">RA</span>
###xml 721 724 <span type="species:ncbi:9606">JRA</span>
###xml 861 863 <span type="species:ncbi:9606">RA</span>
###xml 864 872 <span type="species:ncbi:9606">patients</span>
###xml 881 884 <span type="species:ncbi:9606">JRA</span>
###xml 885 893 <span type="species:ncbi:9606">patients</span>
###xml 965 973 <span type="species:ncbi:9606">patients</span>
###xml 975 977 <span type="species:ncbi:9606">RA</span>
###xml 987 990 <span type="species:ncbi:9606">JRA</span>
In the HLA/TNFA region on chromosome 6p21 we determined allele frequencies of 3 TNFA promotor polymorphisms as well as of polymorphisms in the TNFalpha receptor genes TNFR1 and TNFR2. Additionally, 3 polymorphisms in the IKBL gene located also in 6p21 were investigated. In the TNFA promotor we analysed the -238a/g, -308a/g and the -857c/t polymorphisms (table 2). No differences of allele frequencies were found in both groups of patients compared to the controls. We analysed the promotor polymorphism -609g/t and a nucleotide exchange a/g at position 36 of the coding sequence of the TNFR1 gene. The base exchange does not result in an amino acid substitution (P12P). Both polymorphisms are not associated with RA or JRA (table 2). The allele frequency of a 15 bp deletion in the promotor of the TNFR2 gene has been determined for 428 healthy controls, 190 RA patients and 146 JRA patients. The frequency of the deletion (allele 02) is higher in both groups of patients (RA = 32.9%, JRA = 33.3%, controls = 27.5%; p < 0.05). Statistical significance, however, is lost after Bonferroni correction of the p value (table 2, figure 3). In the IKBL gene we analysed the polymorphisms -332a/g and -132t/a in the promotor and an amino acid exchange C224R in exon 4. The allele frequencies are shown in table 2. The amino acid substitution is probably of functional relevance, since cysteine is a highly reactive and structurally relevant amino acid.
###end p 22
###begin p 23
Allele and genotype frequencies
###end p 23
###begin p 24
###xml 23 25 <span type="species:ncbi:9606">RA</span>
###xml 33 35 <span type="species:ncbi:9606">RA</span>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 46 49 <span type="species:ncbi:9606">JRA</span>
###xml 59 61 <span type="species:ncbi:9606">RA</span>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
CON: healthy controls, RA: adult RA patients, JRA juvenile RA patients
###end p 24
###begin p 25
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFRII </italic>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 122 124 <span type="species:ncbi:9606">RA</span>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 170 173 <span type="species:ncbi:9606">JRA</span>
Allele frequencies of the TNFRII 15 bp deletion in the promotor in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheumatoid arthritis patients (JRA).
###end p 25
###begin p 26
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 453 455 453 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">2</xref>
###xml 164 166 <span type="species:ncbi:9606">RA</span>
###xml 175 178 <span type="species:ncbi:9606">JRA</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 295 302 <span type="species:ncbi:9606">patient</span>
###xml 438 441 <span type="species:ncbi:9606">JRA</span>
###xml 442 450 <span type="species:ncbi:9606">patients</span>
Since the CTLA4 gene is known to play a crucial role in immunological reactions, we analysed the -318c/t polymorphism as well as the T17A exchange in 182 unrelated RA and 138 JRA patients and 362 healthy controls. The allele and genotype frequencies of the T17A exchange are very similar in the patient and in the control groups. A significant association, however, was observed for the promotor polymorphism, especially for the group of JRA patients (pc < 0.001, table 2).
###end p 26
###begin p 27
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC </italic>
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC </italic>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">2</xref>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
###xml 501 505 501 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 534 536 534 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">2</xref>
###xml 575 577 575 577 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 649 651 649 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 720 724 720 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 753 755 753 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 771 772 771 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 785 787 785 787 <sub xmlns:xlink="http://www.w3.org/1999/xlink">7 </sub>
###xml 933 934 933 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1026 1030 1026 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 1058 1060 1058 1060 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
###xml 1076 1077 1076 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 172 174 <span type="species:ncbi:9606">RA</span>
###xml 178 181 <span type="species:ncbi:9606">JRA</span>
###xml 241 243 <span type="species:ncbi:9606">RA</span>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
###xml 261 264 <span type="species:ncbi:9606">JRA</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 402 404 <span type="species:ncbi:9606">RA</span>
###xml 405 413 <span type="species:ncbi:9606">patients</span>
###xml 422 425 <span type="species:ncbi:9606">JRA</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
###xml 482 484 <span type="species:ncbi:9606">RA</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
###xml 703 706 <span type="species:ncbi:9606">JRA</span>
###xml 829 831 <span type="species:ncbi:9606">RA</span>
###xml 1010 1013 <span type="species:ncbi:9606">JRA</span>
PTPRC and MIF present two other candidate genes for diseases with an immunological background. The c77g (P57P) polymorphism of the PTPRC (CD45) gene is not associated with RA or JRA in our cohorts (table 2). DNA of 347 healthy controls, 195 RA patients and 161 JRA patients has been investigated. In the promotor of the MIF gene we analysed an already known SNP (-173g/c) for 390 healthy controls, 283 RA patients and 212 JRA patients. Allele 02 is underrepresented in the group of RA patients (16.3% vs. 21.0% in the control group, pc < 0.05) (table 2). Furthermore a (CATT)n tetranucleotide block starting at position -794 was analysed. The (CATT)5 allele appears significantly more frequently in the JRA group (16.5% vs. 11.0% in the control group, pc < 0.02) (figure 4). The (CATT)7 allele is slightly overrepresented in the RA group, statistical significance, however, is lost after Bonferroni correction of the p value (figure 4). Evaluation of the genotypes yielded an overrepresentation of 0507 in the JRA group (9.4% vs. 4.0% in the control group, pc < 0.06) (figure 4).
###end p 27
###begin p 28
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 121 123 <span type="species:ncbi:9606">RA</span>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 169 172 <span type="species:ncbi:9606">JRA</span>
a,b: Allele and genotype frequencies of the MIF microsatellite in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheumatoid arthritis patients (JRA).
###end p 28
###begin p 29
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNG </italic>
###xml 278 283 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNG </italic>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 143 145 <span type="species:ncbi:9606">RA</span>
###xml 166 169 <span type="species:ncbi:10116">rat</span>
###xml 203 208 <span type="species:ncbi:9606">human</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
Furthermore, we genotyped 4 microsatellites, one in intron 1 of the IFNG gene and 3 in a region on chromosome 17 for which an association with RA has been shown in a rat model as well as in a study with human DNA. The allele frequencies of the microsatellite in intron 1 of the IFNG gene as well of the three chromosome 17 markers (D17S807, D17S1821, D17S795) do not differ between the patients and the controls (Figures 5, 6).
###end p 29
###begin p 30
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNG </italic>
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 104 106 <span type="species:ncbi:9606">RA</span>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 152 155 <span type="species:ncbi:9606">JRA</span>
Allele frequencies of the IFNG microsatellite in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheumatoid arthritis patients (JRA).
###end p 30
###begin p 31
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs. </italic>
###xml 135 137 <span type="species:ncbi:9606">RA</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 183 186 <span type="species:ncbi:9606">JRA</span>
a-c: Allele frequencies of the D17S795, D17S807 and D17S1821 microsatellites in healthy controls (CON) vs. adult rheumatoid arthritis (RA) and juvenile rheumatoid arthritis patients (JRA).
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 0 2 <span type="species:ncbi:9606">RA</span>
###xml 7 10 <span type="species:ncbi:9606">JRA</span>
###xml 396 398 <span type="species:ncbi:9606">RA</span>
###xml 403 406 <span type="species:ncbi:9606">JRA</span>
RA and JRA are two distinct disease entities sharing some clinical and pathogenetic factors as well as a genetic background. Both are complex disorders caused by still unknown environmental influences and by probably manifold variations in an unknown number of predisposing genes. To evaluate genetic susceptibility loci several immunorelevant polymorphisms have been genotyped for both cohorts (RA and JRA) and compared to healthy controls.
###end p 33
###begin p 34
###xml 59 68 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 112 120 112 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04 </italic>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 292 301 292 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 21 23 <span type="species:ncbi:9606">RA</span>
###xml 28 31 <span type="species:ncbi:9606">JRA</span>
###xml 100 102 <span type="species:ncbi:9606">RA</span>
###xml 315 317 <span type="species:ncbi:9606">RA</span>
###xml 372 374 <span type="species:ncbi:9606">RA</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
The manifestation of RA and JRA is associated with certain HLA-DRB1 alleles [3]. The association of RA with the DRB1*04 allele was first defined by Stastny et al. [36] Subsequently, this association has been observed in a majority of populations belonging to different ethnic groups [1]. The HLA-DRB1 typing of our RA cohort confirmed this association. Thus our cohort of RA patients comprises a representative random sample.
###end p 34
###begin p 35
###xml 19 31 19 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*01 </italic>
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*04 </italic>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 347 359 347 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*08 </italic>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">*11 </italic>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 767 772 763 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 822 828 818 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR1 </italic>
###xml 832 838 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR2 </italic>
###xml 861 866 857 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 971 973 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1071 1073 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1346 1348 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1430 1431 1422 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1624 1631 1616 1623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04</italic>
###xml 1685 1687 1677 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1991 1993 1975 1977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 97 100 <span type="species:ncbi:9606">JRA</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 415 418 <span type="species:ncbi:9606">JRA</span>
###xml 663 665 <span type="species:ncbi:9606">RA</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
###xml 1128 1136 <span type="species:ncbi:9606">patients</span>
###xml 1138 1140 <span type="species:ncbi:9606">RA</span>
###xml 1145 1148 <span type="species:ncbi:9606">JRA</span>
###xml 1237 1245 <span type="species:ncbi:9606">patients</span>
###xml 1425 1428 <span type="species:ncbi:9606">JRA</span>
###xml 1502 1510 <span type="species:ncbi:9606">patients</span>
###xml 1558 1561 <span type="species:ncbi:9606">JRA</span>
###xml 1618 1620 <span type="species:ncbi:9606">RA</span>
###xml 1738 1740 <span type="species:ncbi:9606">RA</span>
###xml 1776 1784 <span type="species:ncbi:9606">patients</span>
###xml 2013 2015 <span type="species:ncbi:9606">RA</span>
###xml 2150 2152 <span type="species:ncbi:9606">RA</span>
The association of HLA-DRB1*01 and *04 alleles described in the literature is not obvious in the JRA cohort presented here [8,9]. Possible explanations include that the representation of different subclasses in this heterogenous group of patients is not similar to previous collections because of the limited number of participating patients. The HLA-DRB1*08 and *11 alleles, however, appear more frequently in the JRA group than in the control group corresponding to literature data [10]. Since the HLA region on 6p21 is highly interesting concerning autoimmune diseases and because of the presence of increased levels of TNFalpha in serum and synovial fluid of RA patients promoting tissue damage and joint destruction, several polymorphisms in the promotor of the TNFA gene on 6p21 as well as in the TNF receptor genes TNFR1 and TNFR2 were investigated. The TNFA locus is located within the HLA class III region. Five microsatellite markers (a-e) have been described [37]. TNFa was analyzed in this study. The allele frequencies are similar to those of other studies [38]. TNFa2 is the most frequent allele in both groups of patients (RA and JRA) as well as in the control group, but a significant difference of the frequency between patients and controls has not been observed. TNFa2 was found to be associated with high TNFalpha production [39]. Zake et al. found evidence for a positive association of this allele with JRA [5]. The contradictory data may result from the different origins of the patients. TNFa6 is significantly overrepresented in the JRA group of this study. A strong association of TNFa6 with RA in DRB1*04-negative haplotypes was also shown by Tuokko et al. [40] The mechanisms behind the TNFa6 association with RA has not been clarified yet, but in patients with insulin-dependent diabetes mellitus the TNFa6 allele has been reported to be associated with decreased TNFalpha secretion, wheras the TNFa2 allele was associated with high TNFalpha secretion capacity [39]. The coherency of RA-associated TNFa6 and low TNFalpha secretion is not in accordance with the known involvement of this cytokine in tissue destruction in RA, but the complex pathogenic mechanisms are not understood in detail until now.
###end p 35
###begin p 36
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 278 283 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 537 542 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 926 936 926 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0405 </italic>
###xml 1171 1180 1171 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 1198 1203 1198 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFA </italic>
###xml 662 664 <span type="species:ncbi:9606">RA</span>
###xml 668 671 <span type="species:ncbi:9606">JRA</span>
###xml 850 852 <span type="species:ncbi:9606">RA</span>
###xml 853 861 <span type="species:ncbi:9606">patients</span>
###xml 1138 1140 <span type="species:ncbi:9606">RA</span>
In the TNFA promotor are described at least 11 polymorphisms and numerous studies have been undertaken to determine whether these polymorphisms have any functional significance [11,12,41]. The results of these studies, however, have been conflicting. Some authors conclude that TNFA genotypes influence immunologic diseases while others suggest that TNFA promotor polymorphisms exert no functional effects but exist only because they are in linkage disequilibrium with HLA alleles [42,43]. In this study, three promotor polymorphisms of TNFA have been chosen to analyse, -857c/t, -308a/g and -238a/g. No association was found for any of those polymorphisms with RA or JRA. The obtained allele frequencies are comparable with the results of other studies on Caucasians [43-45]. In contrast, Seki et al. found that the frequency of the -857t allele in RA patients is significantly higher than in the controls [46]. However, the DRB1*0405 allele, which is in linkage disequilibrium with the -857t allele, is more strongly associated with disease susceptibility than the -857t allele. Thus the authors concluded that a susceptibility gene to RA is more closely linked to the HLA-DRB1 locus than to the TNFA locus.
###end p 36
###begin p 37
###xml 228 230 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 265 270 261 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR1</italic>
###xml 331 333 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 491 493 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 605 611 601 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR1 </italic>
###xml 645 647 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 648 650 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 831 833 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 111 113 <span type="species:ncbi:9606">RA</span>
###xml 157 161 <span type="species:ncbi:10090">mice</span>
###xml 768 770 <span type="species:ncbi:9606">RA</span>
###xml 774 777 <span type="species:ncbi:9606">JRA</span>
Since TNFalpha acts via binding to cell surface receptors I and II, their genes are interesting candidates for RA. Furthermore animal models have shown that mice deficient in TNFR have a more severe early inflammatory response [47]. The gene of the TNF receptor 1 (TNFR1) is localized on chromosome 12p13 and consists of 10 exons [48]. Each of the four protein repeats comprising the extracellular ligand binding domain and characterizing a receptor superfamily is interrupted by an intron [48]. The promotor polymorphism -609g/t and a nucleotide exchange a/g at position 36 of the coding sequence of the TNFR1 gene were analysed in this study [48,49]. The base exchange does not result in an amino acid substitution (P12P). Both polymorphisms are not associated with RA or JRA. This result confirms the findings of Barton et al. [50].
###end p 37
###begin p 38
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR2</italic>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 769 775 769 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFR2 </italic>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
###xml 725 727 <span type="species:ncbi:9606">RA</span>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
The gene of the TNF receptor 2 (TNFR2) is localized on chromosome 1p36.2. The 10 exons span 26 kb [51]. In the 5' untranslated region a 15 bp insertion/deletion polymorphism is located between positions -363 to -349 [49]. In this polymorphic region there is similarity to a putative transcription factor binding site. A regulatous function could not be ascribed to this section [52]. Thus the deletion is probably not of functional relevance. The allele frequencies of the deletion are higher in both groups of patients, but statistical significance is lost after Bonferroni correction. Barton et al. [50] and Dieude et al. [53] presented evidence that TNFR2 plays a major role in a subset of families with multiple cases of RA [50,53]. A polymorphism in exon 6 of the TNFR2 gene has been analysed [50,53]. The cohorts in this study did not encompass a sufficient number of patients with family history to warrant investigation of this specific exonic marker.
###end p 38
###begin p 39
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 283 288 279 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 428 430 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 438 443 422 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBL </italic>
###xml 652 654 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 489 491 <span type="species:ncbi:9606">RA</span>
###xml 834 836 <span type="species:ncbi:9606">RA</span>
###xml 840 843 <span type="species:ncbi:9606">JRA</span>
###xml 880 888 <span type="species:ncbi:9606">patients</span>
Near the TNF cluster at the telomeric end of the MHC on chromosome 6p21.3 the IKBL gene is located coding for a 381 amino acid protein and spanning 13.5 kb of genomic DNA [13]. The protein contains ankyrin motifs similar to those of the I-kappa-B (IkappaB) family of proteins. Since IKBL shares homology with other members ot the IkappaB family, it may interact with NFkappaB and regulate acute phase proteins such as TNFalpha [54]. Thus IKBL is not only an interesting candidate gene for RA susceptibility because of the position on 6p21.3. In this study two promotor polymorphisms as well as a non-synonymous substitution (C224R) have been analysed [55]. The amino acid exchange lies in a predicted phosphorylation site and it possibly alters the function of the IkappaBL protein. None of the three polymorphisms is associated with RA or JRA in our cohorts. Further analysis of patients with other autoimmune diseases may elucidate the functional meaning especially of the amino acid substitution.
###end p 39
###begin p 40
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 445 451 445 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 478 480 478 480 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 851 857 851 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1323 1329 1323 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4 </italic>
###xml 729 731 <span type="species:ncbi:9606">RA</span>
###xml 1057 1059 <span type="species:ncbi:9606">RA</span>
###xml 1060 1068 <span type="species:ncbi:9606">patients</span>
###xml 1107 1110 <span type="species:ncbi:9606">JRA</span>
###xml 1111 1119 <span type="species:ncbi:9606">patients</span>
###xml 1237 1245 <span type="species:ncbi:9606">patients</span>
###xml 1358 1360 <span type="species:ncbi:9606">RA</span>
###xml 1368 1371 <span type="species:ncbi:9606">JRA</span>
CTLA4 is expressed on activated T cells binding to the ligands, B7-1 and B7-2 and it is predicted to down-regulate T cell function [56,57]. These observations suggest that the CTLA4 / B7 interaction plays a critical role in regulating self-tolerance and in susceptibility to autoimmune diseases. The CTLA4 gene comprises 3 exons in addition to the leader sequence and maps to chromosome 2q33 [58]. Three polymorphisms have been described in the CTLA4 gene: a microsatellite (AT)n at position 642 of the 3'untranslated region of exon 4 and two SNPs, in exon 1 a a49g base exchange leading to an amino acid substitution T17A in the leader sequence and a c/t transition at position -318 of the promoter sequence [59-61]. Studies on RA as well as on insulin-dependent diabetes mellitus and some other autoimmune diseases suggest an association with these CTLA4 polymorphisms [16-21]. In this study we analysed the -318c/t polymorphism and the a49g exchange. A remarkable difference of the allele frequency of the promotor polymorphism was found in the group of RA patients and even more clearly in the group of JRA patients. The distribution of alleles of the more interesting amino acid exchange, however, does not show differences between patients and controls. Further investigations are needed to clarify the importance of CTLA4 as a susceptibility gene for RA and/or JRA.
###end p 40
###begin p 41
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC </italic>
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC </italic>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1455 1457 1455 1457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1458 1460 1458 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 453 455 <span type="species:ncbi:9606">RA</span>
###xml 996 998 <span type="species:ncbi:9606">RA</span>
###xml 999 1007 <span type="species:ncbi:9606">patients</span>
###xml 1234 1242 <span type="species:ncbi:9606">patients</span>
Furthermore, the PTPRC gene has been investigated here [22]. PTPRC is localized on chromosome 1q31-q32 and consists of 35 exons. The gene encodes a 180-220 kDa glycoprotein expressed on leukocytes and hematopoietic progenitors [22]. This receptor is involved in T and B cell activation and in signal transduction by regulating protein-tyrosine kinases. Because of this involvement in immunological processes, the gene is another important candidate for RA predisposition. The protein exists in multiple isoforms, depending on alternative splicing of exons 4 (CD45RA), 5 (CD45RB) and 6 (CD45RC) (in CD45RO exons 4-6 are spliced out). The already known c77g (P57P) transition in exon 4 was analysed in our cohorts. This polymorphism does not change the amino acid sequence, but it is probably part of a motif necessary for splicing of CD45RA. The expression of CD45RA is increased in 77c/g heterozygous individuals [62]. The frequency of 77c/g heterozygotes is slightly increased in both groups of RA patients compared to the controls, but the result is not statistically significant. Maybe this gene is more important for predisposition to other autoimmune diseases. The c77g polymorphism has been investigated in several studies with patients suffering from MS. The reported results, however, are controversial. Jacobsen et al. demonstrated an association of this polymorphism with MS in three families whereas 3 studies excluded MS association later on [62-65].
###end p 41
###begin p 42
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 416 420 416 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
###xml 457 459 457 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 629 631 629 631 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 698 702 698 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
###xml 783 785 783 785 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 859 868 859 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 869 871 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 918 920 918 920 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 1070 1072 1070 1072 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 1132 1134 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 1352 1354 1352 1354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 31 33 <span type="species:ncbi:9606">RA</span>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 241 247 <span type="species:ncbi:9606">humans</span>
###xml 881 884 <span type="species:ncbi:9606">JRA</span>
###xml 979 981 <span type="species:ncbi:9606">RA</span>
###xml 1119 1121 <span type="species:ncbi:9606">RA</span>
###xml 1122 1130 <span type="species:ncbi:9606">patients</span>
###xml 1493 1496 <span type="species:ncbi:9606">JRA</span>
###xml 1497 1505 <span type="species:ncbi:9606">patients</span>
###xml 1543 1545 <span type="species:ncbi:9606">RA</span>
MIF is found in the synovia of RA patients. The expression of MIF at sites of inflammation suggested a role in regulating the function in host defense. Expression of MIF correlates well with delayed hypersensitivity and cellular immunity in humans [23,24]. The MIF gene covers only less than 1 kb and has three exons separated by small introns of 189 and 95 bp [66]. So far 4 polymorphisms have been revealed in the MIF gene: a tetranucleotide repeat (CATT)n beginning at nucleotide position -794, a g/c exchange in the promotor at position -173, a t/c substitution in intron 1 and a c/g substitution in intron 2 [67]. The (CATT)n repeat is functionally relevant and it affects the activity of the MIF promotor. 5, 6, 7 and 8 consecutive CATT repeat units have been found. The (CATT)5 allele has the lowest level of basal and stimulated MIF promotor activity in vitro [68]. In the JRA cohort presented here, the (CATT)5 allele is overrepresented compared to the controls and the RA group as well as the 0507 genotype. The presence of the low expression-associated (CATT)5 allele correlates with low disease severity in RA patients [68]. Donn et al. demonstrated that the MIF-173g/c variants result in altered expression of MIF in a cell type-specific manner. Serum levels of MIF are also significantly higher in individuals carrying a MIF-173c allele [69]. In this study the -173g/c polymorphism has been analysed. The c allele appears more frequently in the control group and in the group of JRA patients. The frequency of this allele in the RA group is statistically significantly lower.
###end p 42
###begin p 43
###xml 90 95 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNG </italic>
###xml 127 129 123 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 156 158 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 240 248 232 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 378 380 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 540 542 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 562 567 554 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNG </italic>
###xml 315 317 <span type="species:ncbi:9606">RA</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
###xml 570 572 <span type="species:ncbi:9606">RA</span>
IFNgamma is produced by T lymphocytes in response to antigens. In the first intron of the IFNG gene on 12q14 a polymorphic (CA)n microsatellite is located [26]. Microsatellite allele 02 is associated with high levels of IFNgamma production in vitro. Khani-Hanjani et al. described susceptibility to and severity of RA are associated to different alleles of this microsatellite [28]. In our study no differences in the distribution of alleles was found between patients and controls. A similar result has been observed by Constantin et al. [70]. Thus the role of IFNG in RA susceptibility is not clear today.
###end p 43
###begin p 44
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD79b</italic>
###xml 486 492 486 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ICAM-2</italic>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 728 735 724 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ICAM-2 </italic>
###xml 18 20 <span type="species:ncbi:9606">RA</span>
###xml 83 86 <span type="species:ncbi:10116">rat</span>
###xml 97 99 <span type="species:ncbi:9606">RA</span>
###xml 428 430 <span type="species:ncbi:9606">RA</span>
Recently, a novel RA susceptibility locus on 17q22 homologous to one linked to two rat models of RA was found by linkage and association mapping [34]. We analysed three highly polymorphic microsatellites in this region, but no one is associated with the disease. CD79b, a member of the immunoglobulin superfamily, is located in this region. Owing to the involvement in lymphocyte activation, it is a possible candidate gene for RA predisposition. Another gene located in this region is ICAM-2, which participates in the regulation of apoptosis. It is a cell surface adhesion molecule expressed on the endothelium and is involved in leukocyte recruitment into tissues [71]. TNFalpha and other cytokines are able to down-regulate ICAM-2 expression on the transcriptional level.
###end p 44
###begin title 45
Conclusions
###end title 45
###begin p 46
###xml 0 2 <span type="species:ncbi:9606">RA</span>
###xml 7 10 <span type="species:ncbi:9606">JRA</span>
###xml 775 783 <span type="species:ncbi:9606">patients</span>
RA and JRA are complex diseases the manifestation of which is depending on the presence of an unknown number of predisposing alleles in a susceptible individuum. A gene of major effect has not been identified, but several statistically significant results have to be interpreted sensibly. Some of the investigated biallelic polymorphisms are not informative because of the low frequency of the second allele. Thus these markers are considered as not suitable for detecting genetic association. Clearly in the cases of 'negative' results, association with the genes tested can formally not be excluded, because other unlinked variations within the gene(s) in question may be pathogenetically relevant (and therefore also associated) in our cohorts. The number of investigated patients has to be increased to establish the possibility of subdivison of the cohorts according their clinical symptoms, severity of disease, HLA status and also with respect to individual genetic factors.
###end p 46
###begin title 47
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 47
###begin title 48
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 48
###begin p 49
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 24 26 <span type="species:ncbi:9606">RA</span>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 64 67 <span type="species:ncbi:9606">JRA</span>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 280 282 <span type="species:ncbi:9606">RA</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
###xml 352 354 <span type="species:ncbi:9606">RA</span>
###xml 365 368 <span type="species:ncbi:9606">JRA</span>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
###xml 481 483 <span type="species:ncbi:9606">RA</span>
###xml 494 497 <span type="species:ncbi:9606">JRA</span>
###xml 539 541 <span type="species:ncbi:9606">RA</span>
###xml 559 562 <span type="species:ncbi:9606">JRA</span>
More than 200 unrelated RA patients and more than 200 unrelated JRA patients of German origin were attended by the department of rheumatology of the University Hospital (Magdeburg, Germany) and the department of pediatrics of the Karl-Thiem Hospital (Cottbus, Germany). The adult RA patients met the American College of Rheumatology (ACR) criteria for RA [72]. The JRA patients were recruited according the classification of childhood arthritis [73]. The male/female rate was 1:4 (RA) and 1:2 (JRA); the mean age at onset was 48.6 (14-79; RA) and 10.3 (1-22; JRA) years.
###end p 49
###begin p 50
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 228 240 <span type="species:ncbi:9606">participants</span>
The department of transplantation and immunology of the University Hospital Eppendorf (Hamburg, Germany) provided peripheral blood samples as well as informed consent from more than 400 healthy blood donors. The mean age of the participants was 39.3 (20-70) years. The male/female rate was 1.4 [74].
###end p 50
###begin title 51
PCR and RFLP analysis
###end title 51
###begin p 52
###xml 152 154 145 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 258 275 251 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional File 1</xref>
Polymerase chain reactions (PCRs) were carried out in a final volume of 12.5 mul with 50 ng of DNA, 200 muM dNTP, 1 U Taq Polymerase and 0.1 muCi [alpha32P]-dCTP. Primer sequences, PCR conditions, fragment sizes and restriction enzymes utilized are shown in Additional File 1. PCR cycling started with initial denaturation for 5 minutes at 94degreesC. The annealing temperature of the first cycle was 6degreesC, of the second cycle 3degreesC higher than the remaining 26 cycles to achieve high specificity at the beginning of the reaction and to increase the quantity of PCR products in the following cycles. The annealing time was 1 minute. Extension was performed at 72degreesC for 1 minute with final extension of 5 minutes. Restriction enzyme digestion of PCR products >200 bp was performed according to the manufacturer's recommendations. PCR products were electrophoresed by loading restricted fragments onto vertical denaturing or non-denaturing 6% polyacrylamide (PAA) gels.
###end p 52
###begin title 53
SSCP and sequence analysis
###end title 53
###begin p 54
The native PAA gels used for single-strand conformation polymorphism (SSCP) analysis were carried out at 4degreesC. Each PCR system was tested under two different gel conditions. 5% glycerine was added to the first gel, 2.5% glycerine and 1 M urea to the second. Results were documented by autoradiography. Direct sequencing of PCR products was performed on a 373A sequencing automate using the BigDye Terminator Cycle Sequencing Kit (Applied Biosystems).
###end p 54
###begin title 55
Allele specific hybridization
###end title 55
###begin p 56
###xml 82 99 82 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional File 1</xref>
###xml 626 635 626 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1 </italic>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
Sequences of oligonucleotides used for allele specific hybridization are shown in Additional File 1. These oligonucleotides were designed to locate the discriminating single nucleotide exchange in the middle. PCR fragments were denatured in 0.4 M NaOH and transferred onto nylon membranes, utilizing a robot work station (Biomek 2000, Beckman). Two filters were hybridized in parallel, each with one of the allele-specific oligonucleotides. For control the hybridization probe was stripped and the filters rehybridized with the second oligonucleotide. Results were documented by autoradiography. Oligonucleotide sequences for HLA-DRB1 genotyping were designed according to published sequences or as described previously [75,76].
###end p 56
###begin title 57
Statistics
###end title 57
###begin p 58
###xml 107 109 107 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">c </sub>
Comparisons of the frequencies of alleles were performed by Chi-square test in a 2 x 2 contingency table. Pc values are corrected for the number of all alleles tested using Bonferroni correction.
###end p 58
###begin title 59
List of abbreviations
###end title 59
###begin p 60
CTLA4 cytotoxic T lymphocyte-associated protein 4
###end p 60
###begin p 61
IFNgamma interferon gamma
###end p 61
###begin p 62
IKBL inhibitor of kappa light chain gene enhancer in B cells-like gene
###end p 62
###begin p 63
###xml 0 3 <span type="species:ncbi:9606">JRA</span>
JRA juvenile rheumatoid arthritis
###end p 63
###begin p 64
MIF macrophage migration inhibitory factor
###end p 64
###begin p 65
MS multiple sclerosis
###end p 65
###begin p 66
NFkappaB nuclear factor kappa B
###end p 66
###begin p 67
PAA polyacrylamide
###end p 67
###begin p 68
PCR polymerase chain reaction
###end p 68
###begin p 69
PTPRC protein-tyrosine phosphatase receptor-type C
###end p 69
###begin p 70
###xml 0 2 <span type="species:ncbi:9606">RA</span>
RA rheumatoid arthritis
###end p 70
###begin p 71
SE shared epitope
###end p 71
###begin p 72
SSCP single-strand conformation polymorphism
###end p 72
###begin p 73
TNFalpha tumor necrosis factor alpha
###end p 73
###begin title 74
Authors' contributions
###end title 74
###begin p 75
###xml 131 133 <span type="species:ncbi:9606">RA</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 216 219 <span type="species:ncbi:9606">JRA</span>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
BM, WK and JTE carried out the molecular genetic analyses. SD and JK provided the blood samples and clinical investigations of the RA patients. GB and JO provided the blood samples and clinical investigations of the JRA patients. All authors read and approved the final manuscript.
###end p 75
###begin title 76
Supplementary Material
###end title 76
###begin title 77
Additional File 1
###end title 77
###begin p 78
Primer sequences, PCR conditions and restriction endonucleases
###end p 78
###begin p 79
Click here for file
###end p 79
###begin title 80
Acknowledgements
###end title 80
###begin p 81
###xml 27 35 <span type="species:ncbi:9606">patients</span>
We would like to thank the patients and blood donors for participating in this study and S. Schiwy, G. Rodepeter and M. Schumacher for excellent technical assistance. This work was supported by BMBF (01GG9841).
###end p 81
###begin article-title 82
Genetic basis for rheumatoid arthritis
###end article-title 82
###begin article-title 83
Twin concordance rates for rheumatoid arthritis: results from a nationwide study
###end article-title 83
###begin article-title 84
###xml 40 42 <span type="species:ncbi:9606">RA</span>
HLA-DRB1 alleles as severity markers in RA
###end article-title 84
###begin article-title 85
The shared epitope hypothesis
###end article-title 85
###begin article-title 86
###xml 147 155 <span type="species:ncbi:9606">patients</span>
Major histocompatibility complex class I chain related (MIC) a gene, TNFa microsatellite alleles and TNFB alleles in juvenile idiopathic arthritis patients from Latvia
###end article-title 86
###begin article-title 87
###xml 37 42 <span type="species:ncbi:9606">human</span>
Comparative sequence analysis of the human T cell receptor beta chain in juvenile rheumatoid arthritis and juvenile spondylarthropathies: evidence for antigenic selection of T cells in the synovium
###end article-title 87
###begin article-title 88
Epidemiology of chronic arthritis in childhood
###end article-title 88
###begin article-title 89
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Specific HLA-DR4-associated histocompatibility molecules characterize patients with seropositive juvenile rheumatoid arthritis
###end article-title 89
###begin article-title 90
Juvenile rheumatoid arthritis as a complex genetic trait
###end article-title 90
###begin article-title 91
Subtypes of HLA-DRB1*03, *08, *11, *12, *13 and *14 in onset pauciarticular juvenile chronic arthritis (EOPA) with and without iridocyclitis
###end article-title 91
###begin article-title 92
Tumour necrosis factor polymorphisms in rheumatic diseases
###end article-title 92
###begin article-title 93
Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis
###end article-title 93
###begin article-title 94
###xml 40 45 <span type="species:ncbi:9606">human</span>
Characterization of a novel gene in the human major histocompatibility complex that encodes a potential new member of the I kappa B family of proteins
###end article-title 94
###begin article-title 95
CD28 costimulation prevents cell death during primary T cell activation
###end article-title 95
###begin article-title 96
CTLA4 promotor and exon 1 dimorphismus in multiple sclerosis
###end article-title 96
###begin article-title 97
###xml 31 39 <span type="species:ncbi:9606">patients</span>
CTLA4 polymorphisms in Spanish patients with rheumatoid arthritis
###end article-title 97
###begin article-title 98
Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese
###end article-title 98
###begin article-title 99
Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups
###end article-title 99
###begin article-title 100
###xml 29 37 <span type="species:ncbi:9606">patients</span>
CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis
###end article-title 100
###begin article-title 101
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
###end article-title 101
###begin article-title 102
An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies
###end article-title 102
###begin article-title 103
###xml 24 29 <span type="species:ncbi:9606">human</span>
A point mutation in the human CD45 gene associated with defective splicing of exon A
###end article-title 103
###begin article-title 104
Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids
###end article-title 104
###begin article-title 105
High expression of macrophage migration inhibitory factor in the synovial tissue of rheumatoid joints
###end article-title 105
###begin article-title 106
Virus interference. II: Some properties of interferon
###end article-title 106
###begin article-title 107
Dinucleotide repeat polymorphism in the interferon-gamma (IFNG) gene
###end article-title 107
###begin article-title 108
###xml 79 84 <span type="species:ncbi:9606">human</span>
In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene
###end article-title 108
###begin article-title 109
Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis
###end article-title 109
###begin article-title 110
Role of interferon-gamma gene in rheumatoid arthritis?
###end article-title 110
###begin article-title 111
Interferon gamma gene in rheumatoid arthritis
###end article-title 111
###begin article-title 112
Interferon-gamma microsatellite and rheumatoid arthritis
###end article-title 112
###begin article-title 113
###xml 98 104 <span type="species:ncbi:10090">murine</span>
A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2
###end article-title 113
###begin article-title 114
The CTLA-4 gene region of chromosome 2q33 is linked to and associated with type I diabetes
###end article-title 114
###begin article-title 115
###xml 141 144 <span type="species:ncbi:10116">rat</span>
High resolution linkage and association mapping identifies a novel rheumatoid arthritis susceptibility locus homologous to one linked to two rat models of inflammatory arthritis
###end article-title 115
###begin article-title 116
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study
###end article-title 116
###begin article-title 117
Association of the B-cell alloantigen DRw4 with rheumatoid arthritis
###end article-title 117
###begin article-title 118
###xml 33 38 <span type="species:ncbi:9606">human</span>
Highly informative typing of the human TNF locus using six adjacent polymorphic markers
###end article-title 118
###begin article-title 119
TNFa and b microsatellites in Germany
###end article-title 119
###begin article-title 120
###xml 145 150 <span type="species:ncbi:9606">human</span>
Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus
###end article-title 120
###begin article-title 121
###xml 34 42 <span type="species:ncbi:9606">patients</span>
HLA haplotype analysis in finnish patients with rheumatoid arthritis
###end article-title 121
###begin article-title 122
###xml 20 25 <span type="species:ncbi:9606">human</span>
Polymorphism of the human TNF-alpha promotor - random variation or functional diversity?
###end article-title 122
###begin article-title 123
Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease
###end article-title 123
###begin article-title 124
###xml 67 72 <span type="species:ncbi:9606">human</span>
Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promotor
###end article-title 124
###begin article-title 125
###xml 25 30 <span type="species:ncbi:9606">human</span>
Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promotor polymorphism related to joint damage in rheumatoid arthritis
###end article-title 125
###begin article-title 126
###xml 155 160 <span type="species:ncbi:9606">human</span>
- 308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promotor
###end article-title 126
###begin article-title 127
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Polymorphisms in the 5'-flanking region of tumor necrosis factor-alpha gene in patients with rheumatoid arthritis
###end article-title 127
###begin article-title 128
###xml 113 117 <span type="species:ncbi:10090">mice</span>
Attenuation of collagen-induced arthritis in 55 kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice
###end article-title 128
###begin article-title 129
###xml 17 22 <span type="species:ncbi:9606">human</span>
Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13
###end article-title 129
###begin article-title 130
Polymerase chain reaction - single strand conformation polymorphism or how to detect reliably and efficiently each sequence variation in many samples and many genes
###end article-title 130
###begin article-title 131
Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians
###end article-title 131
###begin article-title 132
###xml 46 51 <span type="species:ncbi:9606">human</span>
Physical mapping and genomic structure of the human TNFR2 gene
###end article-title 132
###begin article-title 133
###xml 84 89 <span type="species:ncbi:9606">human</span>
Cloning, sequencing and partial functional characterization of the 5' region of the human p75 tumor necrosis factor receptor-encoding gene (TNF-R)
###end article-title 133
###begin article-title 134
Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity
###end article-title 134
###begin article-title 135
###xml 14 49 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NFkappa B/Rel transcription factors
###end article-title 135
###begin article-title 136
The central MHC gene IKBL carries a structural polymorphism that is associated with HLA-A3, B7, DR15
###end article-title 136
###begin article-title 137
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
###end article-title 137
###begin article-title 138
CTLA-4 can function as a negative regulator of T cell activation
###end article-title 138
###begin article-title 139
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 100 106 <span type="species:ncbi:10090">murine</span>
###xml 111 116 <span type="species:ncbi:9606">human</span>
Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains
###end article-title 139
###begin article-title 140
###xml 40 45 <span type="species:ncbi:9606">human</span>
Dinucleotide repeat polymorphism at the human CTLA4 gene
###end article-title 140
###begin article-title 141
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
###xml 85 90 <span type="species:ncbi:9606">human</span>
CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location
###end article-title 141
###begin article-title 142
###xml 19 24 <span type="species:ncbi:9606">human</span>
A MseI RFLP in the human CTLA4 promotor
###end article-title 142
###begin article-title 143
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC </italic>
A point mutation in PTPRC is associated with the development of multiple sclerosis
###end article-title 143
###begin article-title 144
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC </italic>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients
###end article-title 144
###begin article-title 145
###xml 16 22 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPRC </italic>
Does 77C-->G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus?
###end article-title 145
###begin article-title 146
###xml 83 91 <span type="species:ncbi:9606">patients</span>
PTPRC (CD45) is not associated with multiple sclerosis in a large cohort of German patients
###end article-title 146
###begin article-title 147
###xml 12 17 <span type="species:ncbi:9606">human</span>
Cloning the human gene for macrophage migration inhibitory factor (MIF)
###end article-title 147
###begin article-title 148
Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis
###end article-title 148
###begin article-title 149
A functional promotor polymorhphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis
###end article-title 149
###begin article-title 150
A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis
###end article-title 150
###begin article-title 151
Interferon gamma gene polymorphism and susceptibility to, and severity of, rheumatoid arthritis
###end article-title 151
###begin article-title 152
###xml 86 91 <span type="species:ncbi:9606">human</span>
Characterisation of the tumour necrosis factor (TNF)-(alpha) response elements in the human ICAM-2 promotor
###end article-title 152
###begin article-title 153
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
###end article-title 153
###begin article-title 154
Classification of childhood arthritis
###end article-title 154
###begin article-title 155
Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations
###end article-title 155
###begin article-title 156
HLA class II nucleotide sequences, 1992
###end article-title 156
###begin article-title 157
Genetic predisposition to multiple sclerosis as revealed by immunoprinting
###end article-title 157

